Copyright
©The Author(s) 2016.
World J Hepatol. Aug 28, 2016; 8(24): 1012-1018
Published online Aug 28, 2016. doi: 10.4254/wjh.v8.i24.1012
Published online Aug 28, 2016. doi: 10.4254/wjh.v8.i24.1012
Ref. | Patients | Refractory ascites | Propranolol dose/day | Follow-up | Mortality | Sepsis |
Serstè et al[22] | 74 | 100% | 40 mg (9); 80 mg (31); 120 mg (1); 160 mg (36) | 8 mo | 63/77 (P < 0.0001 vs No NSBB) | NA |
Galbois et al[40] | 26 | 14 (53.8%) | NA | 6 mo | 21/26 (80.8%) | 100% |
Robins et al[60] | 36 | 100% | 48.9 | 10 mo | 18/36 (50%) survival 18 mo | NA |
Mandorfer et al[39] | 245 | 100% | 40 mg (20-120) | 660 persons/year | Higher transplant free survival (HR = 0.771, P = 0.044) | No correlation between NSBB and SBP (HR = 0.728, P = 0.211) |
Kimer et al[31] | 23 | 100% | 80 mg (40-200) | Retrospective | 15/23 (65.2%) | NA |
Leithead et al[30] | 159 (119 on propranolol) | NA | 80 mg (10-240) | Retrospective | 35/159 (22%) | NA |
Bossen et al[32] | 559 | 46% | NA | 12 mo | 125/559 (22.5%) | NA |
Mookerjee et al[37] | 164 (propranolol 111; nadolol 6; carvedilol 16; other 31) | NA | 40 (20-80; propranolol) | NA | 40/164 vs 63/184 (24.4% vs 34.1%, P = 0.048) | NA |
Similar 6 and 12-mo mortality between groups (P = 0.64 and 0.35 respectively) | ||||||
Pereira et al[33] | 104 | NA | NA | NA | 67% vs 69% (P = ns) | 21% vs 42% (P = ns) |
Mallawaarachchi et al[34] | 75 (8 propranolol) | NA | NA | 28 mo | 60% vs 66% (P = ns) | NA |
Bhutta et al[35] | 308 (nadolol 155; propranolol 64; carvedilol 72, other 62) | NA | NA | NA | Mean survival: 58 d in NSBB group (vs 32 d of control group; P = 0.033) | NA |
Onali et al[36] | 126 | 100% | NA | 4 mo | 20 vs 60 (16% vs 32%; P = 0.002) | NA |
- Citation: Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol 2016; 8(24): 1012-1018
- URL: https://www.wjgnet.com/1948-5182/full/v8/i24/1012.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i24.1012